Modern approach to diagnosis and treatment of seizures in newborns and early age children

Authors

  • V.Yu. Martyniuk Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  • T.K. Znamenska SI «Institute of Pediatrics, Obstetrics and Gynecology named after academician O.М. Lukyanova of the NAMS of Ukraine», Kyiv, Ukraine
  • V.B. Shveikina SI «Institute of Pediatrics, Obstetrics and Gynecology named after academician O.М. Lukyanova of the NAMS of Ukraine», Kyiv, Ukraine
  • V.A. Galagan Medical Genetics Center NDSL «OKHMATDYT» of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • Y.B. Bikshaeva Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  • Kh.I. Shveikina SI «Research Institute of Psychiatry of the Ministry of Health of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.15574/SP.2021.116.56

Keywords:

newborn, epilepsy, epileptic encephalopathy, treatment, antiepileptic drugs, review

Abstract

The article is devoted to the topical problem of neonatology and pediatric neurology — the diagnosis and treatment of seizures in newborns and young children.

The work presents an algorithm for the diagnosis and treatment of epileptic seizures in children. It is indicated that the therapeutic effect of most antiepileptic drugs consists of modulation of voltage-gated and ligand-gated channels of membranes of neurons of the cerebral cortex, enhancement of inhibitory synaptic transmission or inhibition of activating synaptic transmission.

The issues of the pharmacokinetics and pharmacodynamics of antiepileptic drugs are considered, taking into account the age characteristics of the child's body, in particular, newborns and early age children.

The problems of drug interaction were discussed. The properties of individual antiepileptic drugs, which are used in newborns and young children, are considered.

Emphasized are «polar» differences in the work of phenobarbital, which depend on the stage of epileptogenesis, namely: suppression of epileptiform activity at the early stage of epileptogenesis and its enhancement in the already formed epileptic focus (epileptic system).

The literature data on the differentiated treatment of certain epileptic syndromes are presented.

The issues on the prospects for the treatment of genetically determined diseases, which are accompanied by seizures associated with metabolic disorders, are considered. The modern high-tech methods of treatment of these diseases are noted. The role of diet therapy, co-factor therapy in the treatment of hereditary metabolic disorders, in particular, the ketogenic diet as a method of alternative treatment for drug-resistant epilepsy in children, is shown.

No conflict of interest was declared by the authors.

References

Aldenkamp AP, Bodde N. (2005). Behaviour, cognition and epilepsy. Acta Neurol Scand Suppl. 182: 19-25. https://doi.org/10.1111/j.1600-0404.2005.00523.x; PMid:16359429

Allegaert K, Verbesselt R, van den Anker JN et al. (2008). Developmental pharmacology: since neonates are not just small adults. Acta Clin Belg. 63 (1): 16-24. https://doi.org/10.1179/acb.2008.003; PMid:18386761

Al-Zwaini EJ, Al-Ani MM, Mengal AH. (2007). The epidemiology of clinical neonatal seizures in Ramadi city. Neurosciences (Riyadh). 12 (2): 170-172. PMID: 21857606.

Baranov АА, Namazova-Baranova LS, Borovik THE et al. (2017). Methylmalonic aciduria in children: clinical recommendations. Pediatr farmakol. 14 (4): 258-271. https://doi.org/10.15690/pf.v14i4.1757

Bauer J, Elger CE, Hans VH, Schramm J, Urbach H, Lassmann H et al. (2007). Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol. 62 (1): 67-80. https://doi.org/10.1002/ana.21148; PMid:17503512

Baulac M. (2003). Pharmacogenetics and epilepsy: Ion channels and thetapeutic responce. 5-th Sanofi-Synthelabo symposium on epilepsy management: 59.

Baumgartner MR, H'rster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M et al. (2014). Proposed guidelines for the diagnosis and management of methylmalonic and propionic academia. Orphanet J Rare Dis. 9: 130. https://doi.org/10.1186/s13023-014-0130-8; PMid:25205257 PMCid:PMC4180313

Belousova ED. (2010). Russian observational study of the efficacy and tolerability of depakine chrono as first-linemonotherapy for focal epilepsy. Nevrologiya, neiropsikhiatriya, psikhosomatika, Neurology, Neuropsychiatry, Psychosomatics. 2 (3): 47-52. https://doi.org/10.14412/2074-2711-2010-100

Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. (2007). GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 87 (4): 1215-1284. https://doi.org/10.1152/physrev.00017.2006; PMid:17928584

Bender AC, Natola H, Ndong C et al. (2013). Focal Scn1a knockdown induces cognitive impairment without seizures. Neurobiol Dis. 54: 297-307. https://doi.org/10.1016/j.nbd.2012.12.021; PMid:23318929 PMCid:PMC3628954

Bialer M. (2012). Chemical properties of entiepileptic drugs (AEDs). Adv Drug Deliv Rev. 64 (10): 887-895. Epub 2011 Nov 21. https://doi.org/10.1016/j.addr.2011.11.006; PMid:22210279

Boerma RS, Braun KP et al. (2016). Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach. Neurotherapeutics. 13 (1): https://doi.org/10.1007/s13311-015-0386-2; PMid:26297079 PMCid:PMC4720669

Boldyreva SR, Ermakov AYu. (2010). Comparative efficacy of carbamazepine, valproic acid and topiramate in temporal lobe medial epilepsy in children. SS Korsakov. 110 (4): 42-47.

Booth D, Evans DJ. (2004). Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 18 (4): CD004218. https://doi.org/10.1002/14651858.CD004218.pub2; PMid:15495087

Boylan GB, Rennie JM, Chorley G et al. (2004). Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology. 62 (3): 486-488. https://doi.org/10.1212/01.WNL.0000106944.59990.E6; PMid:14872039

Boylan GB, Rennie JM, Pressler RM et al. (2002). Phenobarbitone, neonatal seizures and video-EEG. Arch Dis Child Fetal Neonatal Ed. 86 (3): 165-170. https://doi.org/10.1136/fn.86.3.F165; PMid:11978746 PMCid:PMC1721395

Brodie MJ. (2005). Medical therapy of epilepsy: when to initiate treatment and when to combine? J Neurol 252 (2): 125-130. https://doi.org/10.1007/s00415-005-0735-x; PMid:15729515

Bromfield E, Cavazos J, Sirven J. (2006). An Introduction to Epilepsy. West Hartford (CT): American Epilepsy Society. URL: https://www.ncbi.nlm.nih.gov/books/NBK2508/.

Brunquell PJ, Glennon CM, DiMario FJ Jr et al. (2002). Prediction of outcome based on clinical seizure type in newborn infants. J Pediatr. 140 (6): 707-712. https://doi.org/10.1067/mpd.2002.124773; PMid:12072874

Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM et al. (2016). Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Mol Genet Metab. 119 (3): 187-206. https://doi.org/10.1016/j.ymgme.2016.09.002; PMid:27665271 PMCid:PMC5083179

Cherubin E, Gaiarsa JL, Ben-Ari Y. (1991). GABA: an excitatory transmitter in early postnatal life. Trends Neurosci. 14 (12): 515-519. https://doi.org/10.1016/0166-2236(91)90003-D

Choi J, Nordli DR Jr, Alden TD, DiPatri A Jr, Laux L, Kelley K et al. (2009). Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation. 6: 38. https://doi.org/10.1186/1742-2094-6-38; PMid:20021679 PMCid:PMC2811703

Clancy RR, Legido A. (1991). Postnatal epilepsy after EEG-confirmed neonatal seizures. Epilepsia. 32 (1): 69-76. https://doi.org/10.1111/j.1528-1157.1991.tb05614.x; PMid:1985832

Dadali EL, Sharkova IV, Voskoboeva EYu. (2014). Clinical and genetic characteristics of monogenic idiopathic generalized epilepsies. Nervnye bolezni. 1: 15-21.

Degtyareva АV, Nikitina IV, Orlovskaya IV, Zakharova EYu, Bajdakova GV, Ionov OV et al. (2014). Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. Rossijskij vestnik perinatologii i pediatrii (Russian Bulletin of Perinatology and Pediatrics). 59 (4): 41-47.

Dilena R, Striano P et al. (2016). Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. Brain Dev. 38 (1): 128-131. Epub 2015 Jul 23. https://doi.org/10.1016/j.braindev.2015.07.002; PMid:26212315

Durand GM, Zukin RS. (1993). Developmental regulation of mRNAs Encoding rat brain kainate/AMPA receptors: a northern analysis study. J Neurochem. 61 (6): 2239-2246. https://doi.org/10.1111/j.1471-4159.1993.tb07465.x; PMid:8245974

Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC et al. (2005). NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 11 (11): 1205-1213. Epub 2005 Oct 9. https://doi.org/10.1038/nm1301; PMid:16227993

Ellenberg JH, Hirtz DG, Nelson KB. (1984). Age at onset of seizures in young children. Ann Neurol. 15 (2): 127-131. https://doi.org/10.1002/ana.410150204; PMid:6703653

EMA. (2004, Dec). Discussion paper on the impact of renal immaturity when investigating medicinal products intended for paediatric use: 7. URL: https://www.ema.europa.eu/en/documents/scientific-guide-line/discussion paper-impact-renal-imma.

Evtushenko SK. (2012). Destructive and difficult to treat forms of epilepsy in children. MNZh. 6 (52): 15-26. URL: http://nbuv.gov.ua/UJRN/Mnzh_2012_6_4.

Falsaperla R, Vitaliti G, Mauceri L et al. (2017). Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study. J Pediatr Neurosci. 12 (1): 24-28. https://doi.org/10.4103/jpn.JPN_172_16; PMid:28553374 PMCid:PMC5437782

Fanos V, Yurdakok M. (2010). Personalized neonatal medicine. J Matern Fetal Neonatal Med. 23: 4-6. https://doi.org/10.3109/14767058.2010.513103; PMid:20822336

Favrais G, Ursino M, Mouchel C et al. (2019). Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II tri-al. BMJ Open. 9 (1): e022739. https://doi.org/10.1136/bmjopen-2018-022739; PMid:30679288 PMCid:PMC6347888

Filippi L, Fiorini P, Daniotti M et al. (2012). Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI). BMC Pediatr. 12: 144. doi: 10.1186/ 1471-2431-12-144.

Filippi L, Poggi C, la Marca G et al. (2010). Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr. 157 (3): 361-366. https://doi.org/10.1016/j.jpeds.2010.04.019; PMid:20553846

Fisher A, Patsalos PN. (2004). Pharmacology of antiepileptic drugs. In book Wallace SJ, Farrell K et al. Epilepsy in children. London: Arnold. 358-383. URL: https://books.google.com.ua/books?hl=uk&lr=&id=byisCQAAQBAJ&oi=fnd&pg=PP1&dq=Epilepsy+in+children+/+S.+J.+Wallace,+K.+Farrell+%5Bet+al.%5D.&ots=LiPlOYPBUp&sig=eNLXn9xzBKXezzbrcuRRxsCTFRw&redir_esc=y#v=onepage&q=Epilepsy%20in%20children%20%2F%20S.%20J.%20Wallace%2C%20K.%20Farrell%20%5Bet%20al.%5D.&f=false.

Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E et al. (2017). Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58 (4): 522-530. Epub 2017 Mar 8. https://doi.org/10.1111/epi.13670; PMid:28276060

French JA, Kanner AM et al. (2004). Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New-Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 45 (5): 401-409. https://doi.org/10.1111/j.0013-9580.2004.06204.x; PMid:15101821

Ghodke-Puranik Y, Thorn CF, Lamba JK et al. (2013). Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 23 (4): 236-241. https://doi.org/10.1097/FPC.0b013e32835ea0b2; PMid:23407051 PMCid:PMC3696515

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, Langer SZ, Scatton B, Avenet P. (1995). Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol. 47 (6): 1189-1196. PMID: 7603459.

Hirsch E, Genton P. (2003). Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential? CNS Drugs. 17 (9): 633-640. https://doi.org/10.2165/00023210-200317090-00003; PMid:12828499

Hirsch LJ, Arif H, Buchsbaum R et al. (2007). Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 48 (7): 1351-1359. Epub 2007 Jun 15. https://doi.org/10.1111/j.1528-1167.2007.01043.x; PMid:17573925

Ijff DM, Aldenkamp A. (2013). Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol. 111: 707-718. https://doi.org/10.1016/B978-0-444-52891-9.00073-7; PMid:23622218

Isaac JTR, Ashby MC, McBain CJ. (2007). The Role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 54 (6): 859-871. https://doi.org/10.1016/j.neuron.2007.06.001; PMid:17582328

Jin X, Huguenard, JR, Prince DA. (2005). Impaired Cl- extrusion in layer V pyramidal neurons of chronically injured epileptogenic neocortex. Journal of Neurophysiology. 93 (4): 2117-2126. https://doi.org/10.1152/jn.00728.2004; PMid:15774713

Johannessen SI, Landmark CJ. (2008). Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother. 8 (6): 929-939. https://doi.org/10.1586/14737175.8.6.929; PMid:18505358

Karlov VA. (2010). Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin. Moscow: Meditsina: 720.

Khalilov IA. (2020). Vtorichnyy epileptogenez v gippokampe novorozhdennykh krys:… d-ra biol. nauk: 03.03.01. Kazan': 257.

Khan O, Chang E, Cipriani C et al. (2011). Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol. 44 (4): 265-269. https://doi.org/10.1016/j.pediatrneurol.2010.11.005; PMid:21397167

Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. (2004). Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia. 45 (3): 255-262. https://doi.org/10.1111/j.0013-9580.2004.30503.x; PMid:15009227

Klitgaard H,Verdru P. (2007). Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2 (11): 1537-1545. https://doi.org/10.1517/17460441.2.11.1537; PMid:23484603

Kumar SS, Bacci A, Kharazia V, Huguenard JR. (2002). A developmental switch of AMPA receptor subunits in neocortical pyramidal neurons. J Neurosci. 22 (8): 3005-3015. https://doi.org/10.1523/JNEUROSCI.22-08-03005.2002; PMid:11943803 PMCid:PMC6757523

Kwan P, Arzimanoglou A, Berg A et al. (2010). Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 51 (6): 1069-1077. Epub 2009 Nov 3. https://doi.org/10.1111/j.1528-1167.2009.02397.x; PMid:19889013

Lau CG, Zukin RS. (2007). NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nature Reviews Neuroscience. 8 (6): 413-426. https://doi.org/10.1038/nrn2153; PMid:17514195

Liu SJ, Zukin RS. (2007). Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends In Neurosciences. 30 (3): 126-134. Epub 2007 Feb 1. https://doi.org/10.1016/j.tins.2007.01.006; PMid:17275103

Loddenkemper T, Talos DM, Cleary RT, Joseph A, Fernandez Sanchez I et al. (2014). Subunit composition of glutamate and gamma-aminobutyric acid receptors in status epilepticus. Epilepsy Res. 108 (4): 605-615. Epub 2014 Feb 2. https://doi.org/10.1016/j.eplepsyres.2014.01.015; PMid:24613745 PMCid:PMC6294571

Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K et al. (2004). Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. 62 (10): 1668-1681. https://doi.org/10.1212/01.WNL.0000127773.72699.C8; PMid:15159460 PMCid:PMC2937178

Mao X-Y, Cao Y-G, Ji Z et al. (2015). Topiramate protects against glutamate excitotoxicity via activating BDNF/TrkB-dependent ERK pathway in rodent hippocampal neurons. Prog Neuropsychopharmacol Biol Psychiatry. 60: 11-7. Epub 2015 Feb 7. https://doi.org/10.1016/j.pnpbp.2015.01.015; PMid:25661849

McTague A, Cross JH. (2013). Treatment of epileptic encephalopathies. CNS Drugs. 27 (3): 175-184. https://doi.org/10.1007/s40263-013-0041-6; PMid:23397290

Milsap RL, Jusko WJ. (1994). Pharmacokinetics in the Infant. Environ Health Perspect. 102 (11): 107-110. https://doi.org/10.1289/ehp.94102s11107; PMid:7737034 PMCid:PMC1566769

Ministry of Health of Russia. (2017). Phenylketonuria and disturbances of a tetrahydrobiopterine metabolism in children. Clinical recommendations.

Ministry of Health of Ukraine. (2014). «About the consolidation and implementation of medical and technological documents for standardization of medical aid in patients with epilepsy». Order of the Ministry of Health of Ukraine dated April 17, 2014 No. 276. URL: https://zakon.rada.gov.ua/rada/show/v0276282-14#Text.

Morselli PL, Franco-Morselli R, Bossi L. (1980). Clinical Pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clinical Pharmacokinetics. 5 (6): 485-527. https://doi.org/10.2165/00003088-198005060-00001; PMid:7002417

Mruk AL, Garlitz KL, Leung NR. (2015). Levetiracetam in neonatal seizures: a review. J Pediatr Pharmacol Ther. 20 (2): 76-89. https://doi.org/10.5863/1551-6776-20.2.76; PMid:25964725 PMCid:PMC4418685

Mukhin KYu, Petrukhin AS, Choline AA. (2011). Epileptic encephalopathy and similar syndromes in children. Moscow: ArtServis Ltd: 680.

National Clinical Guideline Centre. (2012). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. National Institute for Health and Clinical Excellence: Guidance: 117. PMID: 25340221.

Nikolaeva EА, Kharabadze MN, Zolkina IV, Sukhorukov VS, Novikov PV. (2013). Carnitine insufficiency in children with inborn errors of metabolism and mitochondrial diseases: characteristic of pathogenesis and treatment efficacy. Pediatria. Journal named after GN Speransky. 92 (3): 42-49.

Nikolaeva EА, Yablonskaya MI, Kharabadze MN, Davydova YuI, Komarova ON, Novikov PV. (2015). Biopterine-deficient hyperphenylalaninemia: diagnosis and treatment. Ros vestn perinatol i pediatr (Russian Bulletin of Perinatology and Pediatrics). 60 (2): 61-71.

OMIM. (2021). Sodium voltage-gated channel, alpha subunit 1; scn1a. URL:http://omim.org/entry/182389.

Painter MJ, Scher MS, Stein AD et al. (1999). Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 341 (7): 485-489. https://doi.org/10.1056/NEJM199908123410704; PMid:10441604

Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I et al. (2015). Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 17 (9): 689-701. Epub 2014 Dec 11. https://doi.org/10.1038/gim.2014.177; PMid:25503498 PMCid:PMC5000852

Pathak HR, Weissinger F, Terunuma M, Carlson GC, Hsu FC, Moss SJ, Coulter DA. (2007). Disrupted dentate granule cell chloride regulation enhances synaptic excitability during development of temporal lobe epilepsy. Journal of Neuroscience. 27 (51): 14012-14022. https://doi.org/10.1523/JNEUROSCI.4390-07.2007; PMid:18094240 PMCid:PMC2211568

Patsalos PN, Berry DJ, Bourgeois BF et al. (2008). Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 49 (7): 1239-1276. https://doi.org/10.1111/j.1528-1167.2008.01561.x; PMid:18397299

Patsalos PN. (2005). Antiepileptic drug interactions: a clinical guide. Published by Clarius Press: Guildford. 175. https://doi.org/10.1136/jnnp.2005.085878; PMCid:PMC2077520

Pellegrini-Giampietro DE, Gorter JA, Bennett MV, Zukin RS. (1997). The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders. Trends In Neurosciences. 20 (10): 464-470. https://doi.org/10.1016/S0166-2236(97)01100-4

Perucca E, Gidal BE, Baltes E. (2003). Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53 (1-2): 47-56. https://doi.org/10.1016/S0920-1211(02)00250-4

Perucca E. (2006). Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 61 (3): 246-255. https://doi.org/10.1111/j.1365-2125.2005.02529.x; PMid:16487217 PMCid:PMC1885026

Pickard L, Noel J, Henley JM, Collingridge GL, Molnar E. (2000). Developmental changes in synaptic AMPA and NMDA receptor distribution and AMPA receptor subunit composition in living hippocampal neurons. Journal of Neuroscience. 120 (21): 7922-7931. https://doi.org/10.1523/JNEUROSCI.20-21-07922.2000; PMid:11050112 PMCid:PMC6772733

Plotkin MD, Snyder EY, Hebert SC, Delpire E. (1997). Expression of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat brains: a possible mechanism underlying GABA's excitatory role in immature brain. Journal of Neurobiology. 33 (6): 781-795. https://doi.org/10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5

Pravitelstvo Rossiyskoy Federatsii. (2017). The list of specialized products of clinical nutrition for disabled children for 2018. URL: https://zdrav-dep.admin-smolensk.ru/s_normpravdocs/other/2017/2017-11-08_2466r.pdf.

Rabasseda Х. (2001). Oxcarbazepine: anticonvulsant profile and safety. Drugs Today (Barc). 37 (5): 333-355. https://doi.org/10.1358/dot.2001.37.5.627955; PMid:12768221

Rajasekaran K, Todorovic M, Kapur J. (2012). Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol. 72 (1): 91-102. https://doi.org/10.1002/ana.23570; PMid:22829271 PMCid:PMC3408623

Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, Jensen FE. (2008). Early аlterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. Journal of Neuroscience. 28 (32): 7979-7990. https://doi.org/10.1523/JNEUROSCI.1734-08.2008; PMid:18685023 PMCid:PMC2679369

Ramantani G, Ikonomidou C, Walter B et al. (2011). Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol. 15 (1): 1-7. Epub 2010 Nov 19. https://doi.org/10.1016/j.ejpn.2010.10.003; PMid:21094062

Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. (2008). Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis. 29 (1): 142-160. Epub 2007 Aug 31. https://doi.org/10.1016/j.nbd.2007.08.012; PMid:17931873

Rivera C, Voipio J, Kaila K. (2005). Two developmental switches in GABAergic signalling: the K+-Cl- cotransporter KCC2 and carbonic anhydrase CAVII. J Physiol. 562 (1): 27-36. Epub 2004 Nov 4. https://doi.org/10.1113/jphysiol.2004.077495; PMid:15528236 PMCid:PMC1665491

Saconato H, Prado GF, Puga ME, Atallah AN. (2009). Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Med J. 127 (3): 150-1599. https://doi.org/10.1590/S1516-31802009000300008; PMid:19820875

Sanchez RM, Jensen FE. (2001). Maturational aspects of epilepsy mechanisms and consequences for the immature brain. Epilepsia. 42 (5): 577-585. https://doi.org/10.1046/j.1528-1157.2001.12000.x; PMid:11380563

Scheffer IE, Berkovic S et al. (2017). ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58 (4): 512-521. Epub 2017 Mar 8. https://doi.org/10.1111/epi.13709; PMid:28276062 PMCid:PMC5386840

Scher MS, Alvin J, Gaus L et al. (2003). Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology. 28 (4): 277-280. https://doi.org/10.1016/S0887-8994(02)00621-5

Schirrmacher K, Mayer A, Walden J, Dusing R, Bingmann D. (1995). Effects of carbamazepine on membrane properties of rat sensory spinal ganglion cells in vitro. Eur Neuropsychopharmacol. 5 (4): 501-507. https://doi.org/10.1016/0924-977X(95)00043-O

Schmidt D, Arroyo S et al. (2001). Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand. 104 (3): 167-170. https://doi.org/10.1034/j.1600-0404.2001.00870.x; PMid:11551237

Semenova NA, Dadali EL, Sharkov AA, Akimova IA. (2017). Clinical and genetic characteristics and diagnosis of hereditary variants of neonatal epilepsy. Neuromuscular Diseases. 7 (3): 36-42. https://doi.org/10.17650/2222-8721-2017-7-3-36-42

Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, Makinson CD et al. (2011). Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci. 31 (42): 14850-14860. https://doi.org/10.1523/JNEUROSCI.3922-11.2011

PMid:22016518 PMCid:PMC4126152

Smits A, Kulo A, de Hoon JN, Allegaert K. (2012). Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 18 (21): 3119-3146. https://doi.org/10.2174/1381612811209023119; PMid:22564304

Springer C, Nappe TM. (2019). Anticonvulsants toxicity. StatPearls Publishing: Treasure Island. PMID: 30725891.

Stefani A, Spadoni F, Bernardi G. (1997). Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia. 38 (9): 959-965. https://doi.org/10.1111/j.1528-1157.1997.tb01477.x; PMid:9579933

Studenikin VM, Shelkovsky VI, Pak LA, Goryunova AV and other. (2011). General principles of epilepsy treatment. Ch. 9. Epilepsy in neuropediatrics (collective monograph). Ed. V.M. Studenikin. Moscow: Dynasty: 440.

Svistilnik VO. (2014). The Ketogenic Diet is a Treatment of the Refractory Forms of Epilepsies in Children. Liki Ukrainy plus. 1: 38-40. URL: http://nbuv.gov.ua/UJRN/liku_2014_1_33.

Swanson GT, Kamboj SK, Cull-Candy SG. (1997). Single-channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition. Journal of Neuroscience. 17 (1): 58-69. https://doi.org/10.1523/JNEUROSCI.17-01-00058.1997; PMid:8987736 PMCid:PMC6793687

Talos DM, Fishman RE, Park H, Folkerth RD, Follett PL et al. (2006). Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I Rodent cerebral white matter and cortex. J Comp Neurol. 497 (1): 42-60. https://doi.org/10.1002/cne.20972; PMid:16680782 PMCid:PMC4313670

Talos DM, Follett PL, Folkerth RD, Fishman RE, Trachtenberg FL et al. (2006). Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J Comp Neurol. 497 (1): 61-77. https://doi.org/10.1002/cne.20978; PMid:16680761 PMCid:PMC2987718

Taylor J, Kolamunnage-Dona R, Marson AG, Smith PE, Aldenkamp AP, Baker GA, SANAD study group. (2010). Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia. 51 (1): 48-56. Epub 2009 Jul 2. https://doi.org/10.1111/j.1528-1167.2009.02195.x; PMid:19583779

Tian Y, Guo S-X, Li J-R et al. (2015). Topiramate attenuates early brain injury following subarachnoid haemorrhage in rats via duplex protection against inflammation and neuronal cell death. Brain Res. 1622: 174-185. Epub 2015 Jun 15. https://doi.org/10.1016/j.brainres.2015.06.007; PMid:26086367

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacological Reviews. 62 (3): 405-496. https://doi.org/10.1124/pr.109.002451; PMid:20716669 PMCid:PMC2964903

Uijl SG, Uiterwaal CSPM, Aldenkamp AP, Carpay JA, Doelman JC, Keizer K, Vecht CJ, de Krom MCTFM, van Donselaar CA. (2009). Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial. Eur J Neurol. 16 (11): 1173-1177. Epub 2009 Jun 15. https://doi.org/10.1111/j.1468-1331.2009.02713.x; PMid:19538204

Vento M, De Vries LS, Alberola A et al. (2010). Approach to seizures in the neonatal period: a European perspective. Acta Paediatr. 99 (4): 497-501. https://doi.org/10.1111/j.1651-2227.2009.01659.x; PMid:20055774

Vlasov PN, Orekhova NV, Antonyuk MV, Filatova NV. (2009). Valproate side effects. Klinicheskaya epileptologiya. 1: 3-7.

Watemberg N, Greenstein D, Levine A. (2006). Encephalopathy associated with Hashimoto thyroiditis: pediatric perspective. J Child Neurol. 21 (1): 1-5. https://doi.org/10.1177/08830738060210010201 ;PMid:16551444

Wei F, Yan LM, Su T, He N, Lin ZJ, Wang J, Shi YW, Yi YH, Liao WP. (2017). Ion Channel Genes and Epilepsy: Functional Alteration, Pathogenic Potential, and Mechanism of Epilepsy. Neuroscience Bulletin. 33 (4): 455-477. https://doi.org/10.1007/s12264-017-0134-1; PMid:28488083 PMCid:PMC5567559

WHO. (2011). Guidelines on Neonatal Seizures. World Health Organization. Geneva: 100.

Willow M, Gonoi T, Catterall WA. (1985). Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltagesensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 27 (5): 549-558. PMID: 2581124.

Wirrel E et al. (2013). Stiripentol in Dravet syndrome: Results of a retrospective US study. Epilepsia. 54 (9): 1595-1604. https://doi.org/10.1111/epi.12303; PMid:23848835

Yau ML, Fung EL, Ng PC. (2015). Response of levetiracetam in neonatal seizures. World J Clin Pediatr. 4 (3): 45-49. https://doi.org/10.5409/wjcp.v4.i3.45; PMid:26261766 PMCid:PMC4526838

Zhu JJ, Esteban JA, Hayashi Y, Malinow R. (2000). Postnatal synaptic potentiation: Delivery of GluR4-containing AMPA receptors by spontaneous activity. Nature Neuroscience. 3 (11): 1098-1106. https://doi.org/10.1038/80614; PMid:11036266

Downloads

Published

2021-05-26

Issue

No. 4(116) (2021): Modern Pediatrics. Ukraine

Section

Reviews

License

Copyright (c) 2021 Modern Pediatrics. Ukraine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a  Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).

Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.

Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.

The use of published materials for commercial purposes is strongly prohibited.